Novo Nordisk A/S: Overweight trials

The registry lists 121 Overweight studies with Novo Nordisk A/S as lead sponsor. 33 are open to participants now and 23 have results posted.

Phase 1 60Phase 2 7Phase 3 37Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or ObeseCompletedNCT03707990Phase 1
• Research Study of a New Medicine (NNC9204-1706) in People With Overweight or ObesityCompletedNCT03661879Phase 1
• A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseCompletedNCT03600480Phase 1
• A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or ObeseCompletedNCT03574584Phase 1
• A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.CompletedNCT03560336
• A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or ObesityCompletedNCT03479892Phase 1
• In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care DatabaseCompletedNCT03479762
• Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or ObesityCompletedNCT03308721Phase 1
• Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With ObesityCompletedNCT03095807Phase 1
• First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or ObesityCompletedNCT03015207Phase 1
• Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightCompletedNCT02958085Phase 1
• A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.CompletedNCT02941042Phase 1
• Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02870231Phase 1
• A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With ObesityCompletedNCT02835235Phase 1
• A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.CompletedNCT02717858Phase 1
• Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02300844Phase 1
• Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02235961Phase 1
• A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy VolunteersTerminatedNCT01044108Phase 1
• Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese VolunteersWithdrawnNCT00728455Phase 1
• Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female VolunteersTerminatedNCT00665665Phase 1
• Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 DiabetesCompletedNCT00504673Phase 3